RCS - PureTech Health PLC - PRTC to Give 3 Presentations at CHEST 2024 Meeting

Puretech HealthAnnouncement

01/10/2024 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241001:nRSA3440Ga&default-theme=true

RNS Number : 3440G  PureTech Health PLC  01 October 2024

1 October 2024

PureTech Health plc

 

PureTech to Present at CHEST 2024 Annual Meeting

 

Three presentations inform clinical, commercial and patient engagement
strategies for LYT-100 for the treatment of idiopathic pulmonary fibrosis
(IPF)

 

Topline data from the Phase 2b ELEVATE IPF trial of LYT-100 expected by the
end of 2024

 

PureTech Health plc (https://puretechhealth.com/) (Nasdaq: PRTC, LSE: PRTC)
("PureTech" or the "Company"), a clinical-stage biotherapeutics company
dedicated to changing the lives of patients with devastating diseases, today
announced its onsite presence at the CHEST 2024 Annual Meeting in Boston,
Massachusetts, from October 6-9. The Company will deliver two oral
presentations and one poster relating to LYT-100 (deupirfenidone) for the
treatment of idiopathic pulmonary fibrosis (IPF) as well as the Company's
research surrounding the experiences of patients with IPF.

 

The data to be presented have informed the clinical and commercial strategies
supporting LYT-100 as well as advocacy and patient engagement work around the
management and treatment of people with IPF. Topline results from the Phase 2b
ELEVATE IPF trial are expected by the end of 2024. A streamlined development
program for LYT-100 is planned using the same endpoints that have supported
past IPF product approvals. Pending positive clinical outcomes from the Phase
2b trial and regulatory feedback, the program is expected to advance into a
Phase 3 trial. PureTech believes the results of the Phase 2b trial, together
with a successful Phase 3 trial, could serve as the basis for registration in
the U.S. and other geographies.

 

Presentation Details

 

Presentation Title: Comparing experiences at interstitial lung disease (ILD)
centers and community practices (CP) from the perspective of people with
idiopathic pulmonary fibrosis (IPF)

Session: Oral presentation

Date and Time: October 8, 2024 | 10:20-11:05am EDT

 

Presentation Title: Ongoing burden of idiopathic pulmonary fibrosis (IPF) in
the era of antifibrotics

Session: Poster presentation

Date and Time: October 8, 2024 | 1:45-2:30pm EDT

 

Presentation Title: Bayesian approach for ELEVATE IPF: Randomized,
double-blind, placebo-controlled trial to evaluate efficacy, safety, and dose
response of deupirfenidone (LYT-100) in IPF

Session: Oral presentation

Date and Time: October 8, 2024 | 1:45-2:30pm EDT

 

About Idiopathic Pulmonary Fibrosis (IPF)

IPF is a rare, progressive and fatal lung disease with a median survival of
2-5 years. 1  (#_ftn1)  Pirfenidone is one of only two drugs approved to
treat IPF, and for those patients able to tolerate treatment, it has been
shown to improve survival by approximately 2.5 years compared to supportive
care alone.(1) However, tolerability issues with both of the standard-of-care
drugs result in patients discontinuing treatment or reducing their dose. This
contributes to nearly three out of every four people with IPF choosing to
forego treatment with these otherwise efficacious medicines. 2  (#_ftn2)

 

About LYT-100 (Deupirfenidone)

LYT-100 (deupirfenidone) is being advanced for the treatment of conditions
involving inflammation and fibrosis, including IPF. It is a deuterated form
of pirfenidone that is designed to retain the beneficial pharmacology and
clinically-validated efficacy of pirfenidone with a highly differentiated PK
profile. LYT-100 has also demonstrated favorable tolerability across multiple
clinical studies in more than 400 individuals.

 

Pirfenidone is one of the two standard-of-care treatments approved for IPF,
along with nintedanib, both of which are efficacious but associated with
significant tolerability issues. These tolerability issues result in treatment
discontinuations and/or dose reductions below the FDA-approved dose, thereby
limiting the effectiveness of these otherwise efficacious medicines. With
LYT-100, PureTech aims to deliver better outcomes for patients by enabling
individuals to maintain the same or higher pirfenidone-equivalent doses for
longer. PureTech believes LYT-100 has the potential both to supplant the
current standard-of-care treatments and to serve a larger market of patients
who are unable to tolerate current therapies. Topline data for the global
Phase 2 ELEVATE IPF trial are expected by the end of 2024.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 29 therapeutics and therapeutic candidates,
including three that have been approved by the U.S. Food and Drug
Administration. A number of these programs are being advanced by PureTech or
its Founded Entities in various indications and stages of clinical
development, including registration enabling studies. All of the underlying
programs and platforms that resulted in this pipeline of therapeutic
candidates were initially identified or discovered and then advanced by the
PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com) or connect with us on X (formerly Twitter)
@puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation those related to the LYT-100 development program
and development plans, its potential benefits to patients, the timing for
results from the Phase 2b clinical trial of LYT-100, the advancement of the
program into a Phase 3 trial, and our future prospects, developments and
strategies. The forward-looking statements are based on current expectations
and are subject to known and unknown risks, uncertainties and other important
factors that could cause actual results, performance and achievements to
differ materially from current expectations, including, but not limited to,
those risks, uncertainties and other important factors described under the
caption "Risk Factors" in our Annual Report on Form 20-F for the year ended
December 31, 2023, filed with the SEC and in our other regulatory filings.
These forward-looking statements are based on assumptions regarding the
present and future business strategies of the Company and the environment in
which it will operate in the future. Each forward-looking statement speaks
only as at the date of this press release. Except as required by law and
regulatory requirements, we disclaim any obligation to update or revise these
forward-looking statements, whether as a result of new information, future
events or otherwise.

 

Contact:

PureTech

Public Relations

publicrelations@puretechhealth.com (mailto:publicrelations@puretechhealth.com)

Investor Relations

 

UK/EU Media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

puretech@fticonsulting.com (mailto:puretech@fticonsulting.com)

 

US Media

Nichole Bobbyn

+1 774 278 8273

nichole@tenbridgecommunications.com
(mailto:nichole@tenbridgecommunications.com)

 

 1  (#_ftnref1) Fisher, M., Nathan, S. D., Hill, C., Marshall,
J., Dejonckheere, F., Thuresson, P., & Maher, T. M. (2017). Predicting
Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis. Journal of
Managed Care & Specialty Pharmacy, 23(3-b Suppl), S17-S24.
 https://doi.org/10.18553/jmcp.2017.23.3-b.s17
(https://doi.org/10.18553/jmcp.2017.23.3-b.s17)

 2  (#_ftnref2) Dempsey TM, Payne S, Sangaralingham L, Yao X, Shah ND, Limper
AH. Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for
Patients with Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2021
Jul;18(7):1121-1128

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEANNEDFPLEFA